The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination
https://doi.org/10.21518/2079-701X-2019-4-44-51
Abstract
Hyperglycemia is one of the main risk factors for the development of microvascular complications in patients with T2D. However, the main reason of their deaths remain diseases such as myocardial infarction, chronic heart failure, stroke. Although all of the current glucose-lowering drugs are very effective for the correction of hyperglycemia, studies of the last decade proofs that some of them can additionally decrease cardiovascular risk on patients with T2D. So, the influence of empagliflozin, pioglitazone, liraglutide, semaglutide and canagliflozin was characterized as statistically significant positive to the frequency of development of macrovascular complications in patients with T2D. However, nowadays a convincing reduction in cardiovascular mortality in patients with T2D, who took empagliflozin and liraglutide was demonstrated only in two clinical studies - EMPA-REG OUTCOME and LEADER.
In the following review there are going to be analyzed the significant results of these studies and the peculiarities of the action of these drugs, which, possibly with joint application, have additive effects in reducing cardiovascular risk in patients with T2D.
About the Author
V. V. Salukhov
Federal State Budgetary Military Educational Institution of Higher Education Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
Salukhov Vladimir Vladimirovich - Dr. of Sci. (Med.), Head of the 1st Department and Clinic (for Therapy of Continuing Medical Education).
194044, Saint-Petersburg, 6, Akademika Lebedev Street
References
1. Emerging Risk Factors Collaboration, Di Angelantonio E., Kaptoge S. et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314:52-60.
2. Giorgino F., Home F., Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? Diabetes Care. 2016;39(Suppl. 2):S187-S195. doi: 10.2337/dcS15-3023.
3. DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-1287.
4. Obunai K., Jani S., Dangas G.D. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91:1169-1184.
5. Sattar N. Revisiting the links between glycae-mia, diabetes and cardiovascular disease. Dibetologia. 2013;56:686-695.
6. Zinman B,. Wanner C., Lachin J.M. et al. EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.
7. Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22
8. Salukhov V.V., Demidova T.Yu. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes meUitus. Sakharnyi Diabet. 2016;19(6):494-510. (In Russ.) doi: 10.14341/DM8216.
9. Inzucchi S.E., Zinman B., Wanner C. et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90-100.
10. Fitchett D., Zinman B., Wanner C. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526-1534.
11. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15-30.
12. Nikolaidis L.A., Mankad S., Sokos G.G. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.
13. Ten Kulve J.S., van Bloemendaal L., Balesar R. et al. Decreased hypothalamic glucagon-like peptide-1 receptor expression in type 2 diabetes patients. J Clin Endocrinol Metab. 2016;101(5):2122-2129.
14. Schlatter P., Beglinger C., Drewe J., Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007; 141(1-3): 120-128.
15. Zavattaro M., Caputo M., Sama M.T. et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine. 2015;50(3):620-626.
16. Mizuno Y., Harada E., Nakagawa H. et al. The diabetic heart utilizes ketone bodies as an energy source. Metabolism. 2017;77:65-72.
17. Mudaliar S., Alloju S., Henry R.R. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39(7):1115-22.
18. Kruljac I., CaCiC M., CaCiC P. et al. Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus. Endocrine. 2017; 55(1):139-43.
19. Ismail-Beigi F., Kosiborod M., Inzucchi S.E. et al. Shifting Paradigms in the Medical Management of Type 2 Diabetes:Reflections on Recent Cardiovascular Outcome Trials. J Gen Intern Med. 2017;32(9):1044-51. doi: 10.1007/s11606-017-4061-7.
20. lozzo P., Chareonthaitawee P., Dutka D. et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes. 2002;51:3020-4.
21. Obunai K., Jani S., Dangas G.D. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91:1169-1184.
22. Wanner Ch. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease. Nature Reviews Nephrology. 2018;14:78-80. doi: 10.1038/nrneph.2017.182.
23. Wanner C., Inzucchi S.E., Lachin J.M. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. doi: 10.1056/NEJMoa1515920.
24. Vallon V., Richter K., Blantz R.C., Thomson S., Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10:2569-2576.
25. Sanjay Kaul. Mitigating Cardiovascular Risk in Type 2 DiabetesWith Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care. 2017;40:821-831. https://doi.org/10.2337/dc17-0291.
26. Busch R.S., Kane M.P. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgraduate Medicine. 2017;129(7):686-697. doi: 10.1080/00325481.2017.1342509.
27. Tahrani A.A., Barnett A.H., Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566-592.
28. Nauck M.A., Meier JJ. GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last? Lancet Diabetes Endocrinol. 2016;4:963-964
Review
For citations:
Salukhov VV. The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination. Meditsinskiy sovet = Medical Council. 2019;(4):44-51. (In Russ.) https://doi.org/10.21518/2079-701X-2019-4-44-51
Views:
718
Email this article 